Tolterodine tartrate (BioDeep_00000733366)
代谢物信息卡片
Tolterodine tartrate
化学式: C26H37NO7 (475.2569892)
中文名称: 酒石酸托特罗定
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(C(C(=O)O)O)(C(=O)O)O
InChI: 1-,2-/m11/s1
描述信息
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
D000089162 - Genitourinary Agents > D064804 - Urological Agents
Tolterodine Tartrate (Kabi-2234; PNU-200583E) is a potent muscarinic receptor antagonist and shows selectivity for the urinary bladder over salivary glands in vivo.
同义名列表
4 个代谢物同义名
Tolterodine tartrate; Kabi-2234; PNU-200583E; Tolterodine (tartrate)
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:32245
- KEGGdrug: D01148
- PubChem: 443878
- ChEMBL: CHEMBL1200871
- MeSH: Tolterodine Tartrate
- CAS: 124937-52-6
- medchemexpress: HY-90010
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiangyang Wang, Tongyu Ji, Zhaoqiang Jiang, Jianan Wang, Xiang Su, Lei Shan. Tolterodine ameliorates inflammatory response and ferroptosis against LPS in human bladder epithelial cells.
Journal of biochemical and molecular toxicology.
2023 Sep; ?(?):e23517. doi:
10.1002/jbt.23517. [PMID: 37702107] - Kasım Ertaş, Hanifi Yıldız, Murat Demir, Rahmi Aslan, Recep Eryılmaz, Şevder Kırmızıtoprak, Kerem Taken. Effect of combined use of tolterodine and continuous positive airway pressure vs continuous positive airway pressure only treatment on overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome: a randomized clinical trial.
International urogynecology journal.
2022 07; 33(7):2031-2036. doi:
10.1007/s00192-022-05206-5. [PMID: 35445808] - Frank Donath, Larissa Hoffmann, Marina Todorova-Sanjari, Ralph-Steven Wedemeyer, André Warnke, Klaus Nickisch. Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.
Clinical pharmacology in drug development.
2022 01; 11(1):80-90. doi:
10.1002/cpdd.968. [PMID: 34101369] - Bhavik Patel, Fernando Perez, Patrik Aronsson, Ranya Alothmani, Thomas Carlsson, Michael Winder. Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis.
Pharmacology research & perspectives.
2020 02; 8(1):e00564. doi:
10.1002/prp2.564. [PMID: 32030913] - Christopher R Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers, Emad Siddiqui. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
European urology.
2020 01; 77(1):119-128. doi:
10.1016/j.eururo.2019.09.024. [PMID: 31635815] - Martina S Burczyk, Martin D Burkhalter, Teresa Casar Tena, Laurel A Grisanti, Michael Kauk, Sabrina Matysik, Cornelia Donow, Monika Kustermann, Melanie Rothe, Yinghong Cui, Farah Raad, Svenja Laue, Allessandra Moretti, Wolfram-H Zimmermann, Jürgen Wess, Michael Kühl, Carsten Hoffmann, Douglas G Tilley, Melanie Philipp. Muscarinic receptors promote pacemaker fate at the expense of secondary conduction system tissue in zebrafish.
JCI insight.
2019 10; 4(20):. doi:
10.1172/jci.insight.121971. [PMID: 31619590] - Ji-Yeong Byeon, Choong-Min Lee, Yea-Jin Lee, Young-Hoon Kim, Se-Hyung Kim, Eui Hyun Jung, Won Ki Chae, Yun Jeong Lee, Choon-Gon Jang, Seok-Yong Lee. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine.
Archives of pharmacal research.
2019 Feb; 42(2):182-190. doi:
10.1007/s12272-018-1099-y. [PMID: 30542809] - Yu A Kupriyanov, G R Kasyan, D Yu Pushkar. [A role of fesoterodine in treatment of overactive bladder].
Urologiia (Moscow, Russia : 1999).
2018 Dec; ?(6):155-162. doi:
10.18565/urology.2018.6.155-162. [PMID: 30742396] - Sheng-Mou Hsiao, Ting-Chen Chang, Chi-Hau Chen, Wen-Yih Wu, Ho-Hsiung Lin. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
Lower urinary tract symptoms.
2018 Sep; 10(3):215-220. doi:
10.1111/luts.12167. [PMID: 28436145] - Eric S Rovner, Kyle Raymond, Eugene Andruczyk, Kristian V Juul. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.
Lower urinary tract symptoms.
2018 Sep; 10(3):221-230. doi:
10.1111/luts.12169. [PMID: 28560762] - Nikunjkumar Patel, Barbara Wisniowska, Sebastian Polak. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
The AAPS journal.
2018 07; 20(5):83. doi:
10.1208/s12248-018-0244-3. [PMID: 29995258] - Young Seok Ji, In Sook Kim, Tae Kon Kim, Hye Hyun Yoo. Plasma concentration profile of tolterodine and 5-hydroxymethyl tolterodine following transdermal administration of tolterodine in rats.
Die Pharmazie.
2018 07; 73(7):375-378. doi:
10.1691/ph.2018.8033. [PMID: 30001770] - Robab Maghsoudi, Saeed Farhadi-Niaki, Masoud Etemadian, Amir H Kashi, Pejman Shadpour, Asemaneh Shirani, Rana Samadinezhad-Khoshbaf-Sorkhabi, Meghdad Tabatabaei. Comparing the Efficacy of Tolterodine and Gabapentin Versus Placebo in Catheter Related Bladder Discomfort After Percutaneous Nephrolithotomy: A Randomized Clinical Trial.
Journal of endourology.
2018 02; 32(2):168-174. doi:
10.1089/end.2017.0563. [PMID: 29278929] - Young-Hoon Kim, Ji-Yeong Byeon, Se-Hyung Kim, Choong-Min Lee, Eui Hyun Jung, Won Ki Chae, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee. Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study.
Archives of pharmacal research.
2017 Nov; 40(11):1287-1295. doi:
10.1007/s12272-017-0981-3. [PMID: 29128914] - Jian-Liang Cai, Da Chen, Yu-Feng Song, Jing-Chao Han, Jing-Tian Xiao, Ning-Chen Li, Ming Xia, Yan-Qun Na. [A dosage regimen of M-receptor blocker after TURP for severe BPH with predominant urine storage symptoms].
Zhonghua nan ke xue = National journal of andrology.
2017 Sep; 23(9):793-797. doi:
NULL. [PMID: 29726659] - Abdullah K Alhwiesh, Husain Alsharani, Eman Fathi Ibrahim, Zaid Alanazi, Bushra Ahmed AlGhamdi, Nadia Alaudah, Feras Alzahrani, Adnan Alsarawi, Ashwaqu Almohaws, Ibraheem Saeed Abdurrahman. Recurrent syndrome of inappropriate antidiuretic hormone secretion due to tolterodine in an elderly male patient.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
2017 May; 28(3):625-628. doi:
10.4103/1319-2442.206471. [PMID: 28540903] - Nicolas Monjotin, Martine Farrié, Nathalie Vergnolle, Bruno Le Grand, James Gillespie, Didier Junquero. Bladder telemetry: A new approach to evaluate micturition behavior under physiological and inflammatory conditions.
Neurourology and urodynamics.
2017 02; 36(2):308-315. doi:
10.1002/nau.22970. [PMID: 26879122] - Jing Leng, Limin Liao, Ben Wan, Chuanjun Du, Wei Li, Keji Xie, Zhoujun Shen, Zhuoqun Xu, Shiliang Wu, Zujun Fang, Lulin Ma, Shaomei Han, Cornelia Feustel, Yong Yang, Helmut Madersbacher. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
BJU international.
2017 Jan; 119(1):148-157. doi:
10.1111/bju.13500. [PMID: 27087507] - Dong-Dong Xiao, Jian-Wei Lv, Xin Xie, Xing-Wei Jin, Mu-Jun Lu, Yuan Shao. The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
BMC urology.
2016 Aug; 16(1):49. doi:
10.1186/s12894-016-0167-1. [PMID: 27503124] - N Idkaidek, N Najib, I I Salem, O Najib. Saliva versus Plasma Relative Bioavailability of Tolterodine in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System.
Drug research.
2016 Jun; 66(6):312-5. doi:
10.1055/s-0035-1569442. [PMID: 27011385] - Sri Sivalingam, Necole M Streeper, Priyanka D Sehgal, Brian C Sninsky, Sara L Best, Stephen Y Nakada. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.
The Journal of urology.
2016 Feb; 195(2):385-90. doi:
10.1016/j.juro.2015.08.104. [PMID: 26393904] - Hua Tang, Jian Chen, Yongfu Wang, Ting Yu, Changping Guo, Xiaoqi Liao. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.
Urology journal.
2014 Sep; 11(4):1800-5. doi:
. [PMID: 25194079] - Ximing Liu, Lu Fu, Wenwen Dai, Wei Liu, Jinlong Zhao, Yi Wu, Lengsheng Teng, Fengying Sun, Youxin Li. Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum.
International journal of pharmaceutics.
2014 Aug; 471(1-2):322-31. doi:
10.1016/j.ijpharm.2014.05.051. [PMID: 24882035] - Osamu Yamaguchi, Eiji Marui, Hidehiro Kakizaki, Yukio Homma, Yasuhiko Igawa, Masayuki Takeda, Osamu Nishizawa, Momokazu Gotoh, Masaki Yoshida, Osamu Yokoyama, Narihito Seki, Yasushi Ikeda, Sumito Ohkawa. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
BJU international.
2014 Jun; 113(6):951-60. doi:
10.1111/bju.12649. [PMID: 24471907] - Chunlan Jin, Xinyao Zhou, Ran Pang. Effect of electroacupuncture combined with tolterodine on treating female mixed urinary incontinence.
Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society.
2014 May; 41(3):268-72. doi:
10.1097/won.0000000000000025. [PMID: 24805179] - Tahereh Eftekhar, Nastaran Teimoory, Elahe Miri, Abolghasem Nikfallah, Mahsa Naeimi, Mahsa Ghajarzadeh. Posterior tibial nerve stimulation for treating neurologic bladder in women: a randomized clinical trial.
Acta medica Iranica.
2014; 52(11):816-21. doi:
NULL. [PMID: 25415813] - Yang-Yun Wang, Guo-Wei Shi, Jia-Yang He, Yan-Bin Zhang. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Zhonghua nan ke xue = National journal of andrology.
2013 Dec; 19(12):1099-102. doi:
NULL. [PMID: 24432622] - Fengying Sun, Cheng Sui, Yulin Zhou, Ximing Liu, Yanan Shi, Yi Wu, Youxin Li. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
International journal of pharmaceutics.
2013 Sep; 454(1):532-8. doi:
10.1016/j.ijpharm.2013.07.041. [PMID: 23891744] - Chiu-Lin Wang, Chin-Hu Wu, Cheng-Min Liu, Ching-Ju Shen, Kun-Ling Lin, Cheng-Yu Long. Clinical and urodynamic effects of tolterodine in women with an overactive bladder.
Taiwanese journal of obstetrics & gynecology.
2013 Sep; 52(3):381-4. doi:
10.1016/j.tjog.2012.06.001. [PMID: 24075377] - Abdurrahman Karaman, Emine Samdancı, Sadegül Sayın, Ismail Karabulut, Ersin Fadıllıoglu. Effects of tolterodine and trospium chloride on renal damage induced by partial upper urinary tract obstruction.
Urology.
2013 Jul; 82(1):194-200. doi:
10.1016/j.urology.2013.01.030. [PMID: 23453648] - Chun-Hou Liao, Yu-Chen Kuo, Hann-Chorng Kuo. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.
Urology.
2013 May; 81(5):1030-3. doi:
10.1016/j.urology.2013.01.018. [PMID: 23506731] - Hsin-Tzu Liu, Yuan-Hong Jiang, Hann-Chorng Kuo. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
PloS one.
2013; 8(10):e76706. doi:
10.1371/journal.pone.0076706. [PMID: 24098552] - Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato, Seiji Kaku. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Naunyn-Schmiedeberg's archives of pharmacology.
2013 Jan; 386(1):71-8. doi:
10.1007/s00210-012-0814-3. [PMID: 23224420] - Nasir Idkaidek, Tawfiq Arafat. Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Molecular pharmaceutics.
2012 Aug; 9(8):2358-63. doi:
10.1021/mp300250r. [PMID: 22784220] - Jie Liu, Zhongyan Wang, Chao Liu, Honglei Xi, Chunmei Li, Yang Chen, Lin Sun, Liwei Mu, Liang Fang. Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Drug development and industrial pharmacy.
2012 Aug; 38(8):1008-14. doi:
10.3109/03639045.2011.637049. [PMID: 22126709] - Marwa M Sakr, Rasha M El Nashar. Potentiometric determination of tolterodine in batch and flow injection conditions.
Talanta.
2012 Jul; 96(?):153-60. doi:
10.1016/j.talanta.2012.02.018. [PMID: 22817943] - Yi-Liang' Chen, Wei-Ju Feng, Xiao-Li Zhang. [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication].
Zhongguo zhen jiu = Chinese acupuncture & moxibustion.
2012 Mar; 32(3):215-8. doi:
NULL. [PMID: 22471132] - Itaru Maruyama, Saori Yonekubo, Satoshi Tatemichi, Kazuyasu Maruyama, Yuji Hoyano, Yoshinobu Yamazaki, Hiroshi Kusama. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.
Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.
2012; 48(5-6):115-24. doi:
10.1540/jsmr.48.115. [PMID: 23538508] - Sun-Ouck Kim, Eu Chang Hwang, Kyung Jin Oh, Dongdeuk Kwon, Kwangsung Park, Soo Bang Ryu. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s.
International urogynecology journal.
2011 Oct; 22(10):1287-91. doi:
10.1007/s00192-011-1453-9. [PMID: 21617983] - Ernesto Callegari, Bimal Malhotra, Peter J Bungay, Rob Webster, Katherine S Fenner, Sarah Kempshall, Jennifer L LaPerle, Martin C Michel, Gary G Kay. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
British journal of clinical pharmacology.
2011 Aug; 72(2):235-46. doi:
10.1111/j.1365-2125.2011.03961.x. [PMID: 21392072] - Hiroshi Nagabukuro, Katherine L Villa, L Alexandra Wickham, Alison A Kulick, Loise Gichuru, Marcie J Donnelly, Gregory O Voronin, Tony Pereira, Xinchun Tong, Andrew Nichols, Stephen E Alves, Gary P O'Neill, Christopher V Johnson, Emily J Hickey. Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.
The Journal of pharmacology and experimental therapeutics.
2011 Jul; 338(1):220-7. doi:
10.1124/jpet.111.179747. [PMID: 21459965] - Wen-Yih Wu, Sheng-Mou Hsiao, Ting-Chen Chang, Ho-Hsiung Lin. Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction.
The journal of obstetrics and gynaecology research.
2011 May; 37(5):436-41. doi:
10.1111/j.1447-0756.2010.01370.x. [PMID: 21272154] - Wei Gan, Shao-Feng Zhang, Hong-Tao Jia, Sheng Xie, Mao-Hua Luo, Yun-Fei Li. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
Zhonghua nan ke xue = National journal of andrology.
2011 Apr; 17(4):348-50. doi:
. [PMID: 21548214] - Stine Mjåvatn Jakobsen, Hege Kersten, Espen Molden. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Journal of the American Geriatrics Society.
2011 Mar; 59(3):501-5. doi:
10.1111/j.1532-5415.2010.03307.x. [PMID: 21391941] - Christopher R Chapple, Sender Herschorn, Paul Abrams, Joseph T Wang, Marina Brodsky, Zhonghong Guan. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
BJU international.
2010 Nov; 106(9):1332-8. doi:
10.1111/j.1464-410x.2010.09359.x. [PMID: 20497416] - Fengying Sun, Cheng Sui, Lesheng Teng, Ximing Liu, Lirong Teng, Qingfan Meng, Youxin Li. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres.
International journal of pharmaceutics.
2010 Sep; 397(1-2):44-9. doi:
10.1016/j.ijpharm.2010.06.042. [PMID: 20600717] - Daniel A Shoskes, J Curtis Nickel, Michael W Kattan. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
Urology.
2010 Jun; 75(6):1249-53. doi:
10.1016/j.urology.2010.01.021. [PMID: 20363491] - Philippe Zimmern, Heather J Litman, Elizabeth Mueller, Peggy Norton, Patricia Goode. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women.
BJU international.
2010 Jun; 105(12):1680-5. doi:
10.1111/j.1464-410x.2009.09055.x. [PMID: 19912207] - Ulrich Mehnert, André Reitz, Sumaya Abo Youssef, Brigitte Schurch. Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release.
Neurourology and urodynamics.
2010 Mar; 29(3):464-9. doi:
10.1002/nau.20743. [PMID: 19637377] - Jean-Jacques Wyndaele. Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Nature reviews. Urology.
2010 Feb; 7(2):66-8. doi:
10.1038/nrurol.2010.1. [PMID: 20145662] - Akira Tsujimura, Tetsuya Takao, Kinya Uchida, Keisuke Yamamoto, Shinichiro Fukuhara, Jiro Nakayama, Tomohiro Ueda, Toshiaki Hirai, Hiroshi Kiuchi, Yasushi Miyagawa, Toru Takahashi, Yasuyuki Kojimaan, Akihiko Okuyama. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
2009 Nov; 100(7):686-92. doi:
10.5980/jpnjurol.100.686. [PMID: 19999133] - Stéphane Bolduc, Katherine Moore, Sylvie Lebel, Pascale Lamontagne, Micheline Hamel. Double anticholinergic therapy for refractory overactive bladder.
The Journal of urology.
2009 Oct; 182(4 Suppl):2033-8. doi:
10.1016/j.juro.2009.05.099. [PMID: 19695628] - Ligang Zhao, Yan Li, Liang Fang, Zhonggui He, Xuntao Liu, Lin Wang, Yongnan Xu, Changshu Ren. Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation.
International journal of pharmaceutics.
2009 Jun; 374(1-2):73-81. doi:
10.1016/j.ijpharm.2009.03.005. [PMID: 19446762] - Hsin-Tzu Liu, Michael B Chancellor, Hann-Chorng Kuo. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
BJU international.
2009 Jun; 103(12):1668-72. doi:
10.1111/j.1464-410x.2009.08380.x. [PMID: 19220267] - Jan Macek, Pavel Ptácek, Josef Klíma. Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Apr; 877(10):968-74. doi:
10.1016/j.jchromb.2009.02.036. [PMID: 19269904] - Hans-Uwe Simon, Bimal Malhotra. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Swiss medical weekly.
2009 Mar; 139(9-10):146-51. doi:
smw-12542. [PMID: 19145494] - Claus G Roehrborn, Steven A Kaplan, Stephen R Kraus, Joseph T Wang, Tamara Bavendam, Zhonghong Guan. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Urology.
2008 Nov; 72(5):1061-7; discussion 1067. doi:
10.1016/j.urology.2008.06.067. [PMID: 18817961] - Christopher R Chapple, Philip E Van Kerrebroeck, Klaus-Peter Jünemann, Joseph T Wang, Marina Brodsky. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
BJU international.
2008 Nov; 102(9):1128-32. doi:
10.1111/j.1464-410x.2008.07907.x. [PMID: 18647298] - Yao-Chi Chuang, Catherine A Thomas, Shachi Tyagi, Naoki Yoshimura, Pradeep Tyagi, Michael B Chancellor. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.
International urogynecology journal and pelvic floor dysfunction.
2008 Oct; 19(10):1353-7. doi:
10.1007/s00192-008-0650-7. [PMID: 18504514] - Kim A Madewell, Phil Kuo. Hyponatremia associated with tolterodine therapy.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2008 Jun; 65(11):1054-6. doi:
10.2146/ajhp070535. [PMID: 18499879] - Kinkar Mahanta, Bikas Medhi, Balpinder Kaur, Kannan Laksmi Narasimhan. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities.
Journal of pediatric urology.
2008 Apr; 4(2):118-23. doi:
10.1016/j.jpurol.2007.10.011. [PMID: 18631906] - Sönke Boy, Brigitte Schurch, Ulrich Mehnert, Gudrun Mehring, Gilles Karsenty, André Reitz. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results.
BJU international.
2007 Sep; 100(3):574-8. doi:
10.1111/j.1464-410x.2007.06903.x. [PMID: 17669142] - Jeffrey P Weiss, Jerry G Blaivas, Mark Jones, Joseph T Wang, Zhonghong Guan. Age related pathogenesis of nocturia in patients with overactive bladder.
The Journal of urology.
2007 Aug; 178(2):548-51; discussion 551. doi:
10.1016/j.juro.2007.03.117. [PMID: 17570424] - Yong Yang, Xiao-feng Zhao, Han-zhong Li, Wei Wang, Yong Zhang, He Xiao, Xin Zhang. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Chinese medical journal.
2007 Mar; 120(5):370-4. doi:
. [PMID: 17376305] - Ruth L Martin, Zhi Su, James T Limberis, Jason D Palmatier, Marlon D Cowart, Bryan F Cox, Gary A Gintant. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.
Journal of cardiovascular pharmacology.
2006 Nov; 48(5):199-206. doi:
10.1097/01.fjc.0000246853.15926.d4. [PMID: 17110801] - Yongtae Kim, Naoki Yoshimura, Hitoshi Masuda, Fernando De Miguel, Michael B Chancellor. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
BJU international.
2006 Feb; 97(2):400-3. doi:
10.1111/j.1464-410x.2005.05913.x. [PMID: 16430654] - G Willy Davila. Transdermal oxybutynin in the treatment of overactive bladder.
Clinical interventions in aging.
2006; 1(2):99-105. doi:
10.2147/ciia.2006.1.2.99. [PMID: 18044106] - Pamela I Ellsworth, Niels G Borgstein, Rien J M Nijman, Pramod P Reddy. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
The Journal of urology.
2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. doi:
10.1097/01.ju.0000176622.81796.89. [PMID: 16148673] - Beibei Zhang, Zunjian Zhang, Yuan Tian, Fengguo Xu. High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Sep; 824(1-2):92-8. doi:
10.1016/j.jchromb.2005.07.010. [PMID: 16043426] - Klaus-Peter Jünemann, Michael Halaska, Tomas Rittstein, Gerd Mürtz, Frieder Schnabel, Rainer Brünjes, Wojciech Nurkiewicz. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
European urology.
2005 Sep; 48(3):478-82. doi:
10.1016/j.eururo.2005.04.023. [PMID: 15967567] - Semih Ayan, Kemal Kaya, Kahraman Topsakal, Hakan Kilicarslan, Gokhan Gokce, Yener Gultekin. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children.
BJU international.
2005 Aug; 96(3):411-4. doi:
10.1111/j.1464-410x.2005.05641.x. [PMID: 16042740] - Mats A L Eriksson, Johan Gabrielsson, Lars B Nilsson. Studies of drug binding to plasma proteins using a variant of equilibrium dialysis.
Journal of pharmaceutical and biomedical analysis.
2005 Jul; 38(3):381-9. doi:
10.1016/j.jpba.2005.01.015. [PMID: 15925237] - Rita D Jewart, Joanne Green, Ching-ju Lu, Janet Cellar, Larry E Tune. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
2005 Apr; 13(4):324-8. doi:
10.1176/appi.ajgp.13.4.324. [PMID: 15845759] - Eric S Rovner. Tolterodine for the treatment of overactive bladder: a review.
Expert opinion on pharmacotherapy.
2005 Apr; 6(4):653-66. doi:
10.1517/14656566.6.4.653. [PMID: 15934891] - Rien J M Nijman, Niels G Borgstein, Pamela Ellsworth, Jens C Djurhuus. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
The Journal of urology.
2005 Apr; 173(4):1334-9. doi:
10.1097/01.ju.0000152322.17542.63. [PMID: 15758796] - YongTae Kim, Naoki Yoshimura, Hitoshi Masuda, Fernando de Miguel, Michael B Chancellor. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Urology.
2005 Feb; 65(2):238-42. doi:
10.1016/j.urology.2004.11.021. [PMID: 15708029] - K Giannitsas, P Perimenis, A Athanasopoulos, K Gyftopoulos, G Nikiforidis, G Barbalias. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.
European urology.
2004 Dec; 46(6):776-82; discussion 782. doi:
10.1016/j.eururo.2004.07.021. [PMID: 15548447] - Teng C Hua, Alan Pan, Clark Chan, Yeo K Poo, Michael H Skinner, Mary P Knadler, Celedon R Gonzales, Stephen D Wise. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
British journal of clinical pharmacology.
2004 May; 57(5):652-6. doi:
10.1111/j.1365-2125.2004.02068.x. [PMID: 15089819] - Jiesheng Kang, Xiao-Liang Chen, Hongge Wang, Junzhi Ji, William Reynolds, Sungtaek Lim, James Hendrix, David Rampe. Cardiac ion channel effects of tolterodine.
The Journal of pharmacology and experimental therapeutics.
2004 Mar; 308(3):935-40. doi:
10.1124/jpet.103.062182. [PMID: 14711935] - Gayatri Sathyan, Roger R Dmochowski, Rodney A Appell, Cindy Guo, Suneel K Gupta. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
Clinical pharmacokinetics.
2004; 43(14):1059-68. doi:
10.2165/00003088-200443140-00008. [PMID: 15530134] - Eric S Rovner. Trospium chloride in the management of overactive bladder.
Drugs.
2004; 64(21):2433-46. doi:
10.2165/00003495-200464210-00005. [PMID: 15482001] - A Wagg, J Malone-Lee. Pressure-flow variables in patients treated with tolterodine for detrusor overactivity.
BJU international.
2003 Dec; 92(9):969-71. doi:
10.1111/j.1464-410x.2003.04500.x. [PMID: 14632857] - Y Homma, J S Paick, J G Lee, K Kawabe. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
BJU international.
2003 Nov; 92(7):741-7. doi:
10.1046/j.1464-410x.2003.04468.x. [PMID: 14616458] - Robert Freeman, Simon Hill, Richard Millard, Mark Slack, John Sutherst. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
Obstetrics and gynecology.
2003 Sep; 102(3):605-11. doi:
10.1016/s0029-7844(03)00623-9. [PMID: 12962951] - A Athanasopoulos, K Gyftopoulos, K Giannitsas, J Fisfis, P Perimenis, G Barbalias. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
The Journal of urology.
2003 Jun; 169(6):2253-6. doi:
10.1097/01.ju.0000067541.73285.eb. [PMID: 12771763] - Thomas A Fey, Murali Gopalakrishnan, James G Strake, Linda L King, Jorge D Brioni, James P Sullivan, Michael J Coghlan, Michael E Brune. Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Neurourology and urodynamics.
2003; 22(2):147-55. doi:
10.1002/nau.10103. [PMID: 12579633] - Lynne M Bang, Stephanie E Easthope, Caroline M Perry. Transdermal oxybutynin: for overactive bladder.
Drugs & aging.
2003; 20(11):857-64. doi:
10.2165/00002512-200320110-00007. [PMID: 12964892] - J L C M Dorne, K Walton, W Slob, A G Renwick. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2002 Nov; 40(11):1633-56. doi:
10.1016/s0278-6915(02)00117-5. [PMID: 12176090] - Alan D Garely, Lara J Burrows. Current pharmacotherapeutic strategies for overactive bladder.
Expert opinion on pharmacotherapy.
2002 Jul; 3(7):827-33. doi:
10.1517/14656566.3.7.827. [PMID: 12083983] - A M K Rickwood. Assessment and conservative management of the neuropathic bladder.
Seminars in pediatric surgery.
2002 May; 11(2):108-19. doi:
10.1053/spsu.2002.31810. [PMID: 11973763] - Mohamad Rahimy, Bengt Hallén, Prem Narang. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
Arzneimittel-Forschung.
2002; 52(12):890-5. doi:
10.1055/s-0031-1299986. [PMID: 12572529] - B Olsson, B M Landgren. The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Clinical therapeutics.
2001 Nov; 23(11):1876-88. doi:
10.1016/s0149-2918(00)89083-9. [PMID: 11768839] - C Crandall. Tolterodine: a clinical review.
Journal of women's health & gender-based medicine.
2001 Oct; 10(8):735-43. doi:
10.1089/15246090152636488. [PMID: 11703885] - B Jacquetin, J Wyndaele. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
European journal of obstetrics, gynecology, and reproductive biology.
2001 Sep; 98(1):97-102. doi:
10.1016/s0301-2115(00)00561-3. [PMID: 11516807] - B Olsson, N Brynne, C Johansson, H Arnberg. Food increases the bioavailability of tolterodine but not effective exposure.
Journal of clinical pharmacology.
2001 Mar; 41(3):298-304. doi:
10.1177/00912700122010113. [PMID: 11269570] - I Påhlman, R d'Argy, L Nilvebrant. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.
Arzneimittel-Forschung.
2001 Feb; 51(2):125-33. doi:
10.1055/s-0031-1300014. [PMID: 11258042] - I Påhlman, S Kankaanranta, L Palmér. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
Arzneimittel-Forschung.
2001 Feb; 51(2):134-44. doi:
10.1055/s-0031-1300015. [PMID: 11258043] - B Olsson, J Szamosi. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
Clinical pharmacokinetics.
2001; 40(2):135-43. doi:
10.2165/00003088-200140020-00005. [PMID: 11286323] - B Olsson, J Szamosi. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Clinical pharmacokinetics.
2001; 40(3):227-35. doi:
10.2165/00003088-200140030-00006. [PMID: 11327200]